• AIM ImmunoTech highlighted progress in its Phase 2 DURIPANC trial testing Ampligen with AstraZeneca’s Imfinzi in metastatic pancreatic cancer.
• Final Ampligen dosing is complete; topline results will be presented in the first quarter of 2027.
• Interim updates pointed to immune activation signals; treatment has been well-tolerated with patients reporting high quality of life.
• Separate Netherlands named-patient program data in post-FOLFIRINOX maintenance suggested encouraging survival, safety, and quality-of-life outcomes.
• Management positioned upcoming DURIPANC results, including exploratory biomarkers, as input for designing a planned pivotal trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010902PRIMZONEFULLFEED9837819) on October 01, 2026, and is solely responsible for the information contained therein.